RARE DISEASERESEARCH ATLAS

ORPHA:221139

Combined immunodeficiency with facio-oculo-skeletal anomalies

high confidenceDisorder

Also known as: Roifman-Chitayat syndrome

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

3

15.2th percentile

Trials

0

Interventional, condition-specific

Researchers

25

Distinct authors in sample

Gene link

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

A rare combined immunodeficiency disorder characterized by primary immunodeficiency manifesting with repeated bacterial, viral and fungal infections, in association with neurological manifestations (, cerebellar , myoclonic ), , optic atrophy, facial dysmorphism (high forehead, hypoplastic supraorbital ridges, palpebral edema, hypertelorism, flat nasal bridge, broad nasal root and tip, anteverted nares, thin lower lip overlapped by upper lip, square chin) and skeletal anomalies (short metacarpals/metatarsals with cone-shaped epiphyses, osteopenia).

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

Roifman-Chitayat syndrome, digenic

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    3 matched papers (3 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

3

3 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

3 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

3 in the last 10 years · high confidence · 15.2th percentile (publications denominator)

Phrase hits: 3 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

25

Distinct author names in 3 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    André I1 paper · 2021

    Université de Paris, Imagine Institute, Paris, France.

    Papers in Europe PMC
  2. 02
    Azarnoush S1 paper · 2021

    Hospital Robert Debré, Pediatric Immune-Hematology Service, Paris, France.

    Papers in Europe PMC
  3. 03
    Cavazzana M1 paper · 2021

    Université de Paris, Imagine Institute, Paris, France.

    Papers in Europe PMC
  4. 04
    Chentout L1 paper · 2021

    Université de Paris, Imagine Institute, Paris, France.

    Papers in Europe PMC
  5. 05
    Chitayat D1 paper · 2018

    Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Ontario, Canada.

    Papers in Europe PMC
  6. 06
    Dadi H1 paper · 2018

    Canadian Centre for Primary Immunodeficiency, Immunogenomic Laboratory, Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.

    Papers in Europe PMC
  7. 07
    Durandy A1 paper · 2021

    Université de Paris, Imagine Institute, Paris, France.

    Papers in Europe PMC
  8. 08
    Freeman S1 paper · 2018

    The Program in Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada.

    Papers in Europe PMC
  9. 09
    Grinstein S1 paper · 2018

    The Program in Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada.

    Papers in Europe PMC
  10. 10
    Herbrick JA1 paper · 2018

    Centre for Applied Genomics, Hospital for Sick Children, Toronto, Ontario, Canada.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Combined immunodeficiency with facio-oculo-skeletal anomalies" OR "Roifman-Chitayat syndrome" OR "Roifman-Chitayat syndrome, digenic"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Roifman-Chitayat Syndrome

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Combined immunodeficiency with facio-oculo-skeletal anomalies" OR "Roifman-Chitayat syndrome" OR "Roifman-Chitayat syndrome, digenic"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T09:57:43.684Z